"Kallikreins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77).
| Descriptor ID |
D007610
|
| MeSH Number(s) |
D08.811.277.656.300.760.442 D08.811.277.656.959.350.442 D12.776.124.125.597 D23.119.597
|
| Concept/Terms |
Kallikreins- Kallikreins
- Kalliginogenase
- Kallikrein
- Kininogenase
- Callicrein
- Kallidinogenase
- Kinin-Forming Enzyme
- Enzyme, Kinin-Forming
- Kinin Forming Enzyme
|
Below are MeSH descriptors whose meaning is more general than "Kallikreins".
Below are MeSH descriptors whose meaning is more specific than "Kallikreins".
This graph shows the total number of publications written about "Kallikreins" by people in this website by year, and whether "Kallikreins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 4 | 1 | 5 |
| 1995 | 8 | 1 | 9 |
| 1996 | 13 | 3 | 16 |
| 1997 | 14 | 1 | 15 |
| 1998 | 6 | 1 | 7 |
| 1999 | 5 | 0 | 5 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 3 | 5 |
| 2004 | 1 | 0 | 1 |
| 2005 | 3 | 0 | 3 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 4 | 5 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 2 | 3 |
| 2014 | 1 | 1 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2019 | 0 | 2 | 2 |
| 2020 | 1 | 3 | 4 |
| 2021 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Kallikreins" by people in Profiles.
-
Specific Targeting of Plasma Kallikrein for Treatment of Hereditary Angioedema: A Revolutionary Decade. J Allergy Clin Immunol Pract. 2022 03; 10(3):716-722.
-
A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer. Biomed Pharmacother. 2021 Nov; 143:112226.
-
Analysis of cold activation of the contact system in hereditary angioedema with normal C1 inhibitor. Mol Immunol. 2021 08; 136:150-160.
-
Hereditary angioedema: Investigational therapies and future research. Allergy Asthma Proc. 2020 11 01; 41(Suppl 1):S51-S54.
-
Longitudinal Plasma Kallikrein Levels and Their Association With the Risk of Cardiovascular Disease Outcomes in Type 1 Diabetes in DCCT/EDIC. Diabetes. 2020 11; 69(11):2440-2445.
-
Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. Cancer Treat Res Commun. 2020; 24:100193.
-
sgp120 and the contact system in hereditary angioedema: A diagnostic tool in HAE with normal C1 inhibitor. Mol Immunol. 2020 03; 119:27-34.
-
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data. J Urol. 2020 Apr; 203(4):743-750.
-
FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist. Scand J Urol. 2018 Oct - Dec; 52(5-6):349-357.
-
Meta-Analysis of Prostatic Artery Embolization for Benign Prostatic Hyperplasia. J Vasc Interv Radiol. 2016 Nov; 27(11):1686-1697.e8.